Clinical evaluation of the BD probetec™ chlamydia trachomatis Qx amplified DNA assay on the BD viper™ system with XTR™ technology

Stephanie N. Taylor, Barbara Van Der Pol, Rebecca Lillis, Edward W. Hook, William Lebar, Thomas Davis, Deanna Fuller, Leandro Mena, Paul Fine, Charlotte A. Gaydos, David H. Martin

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: This study evaluated the performance of the BD ProbeTec Chlamydia trachomatis Q (CTQ) Amplified DNA Assay on the BD Viper System with XTR Technology in a multicenter study. Methods: Specimens were collected at 7 geographically diverse clinical sites from 1538 women and men attending sexually transmitted disease, family planning, and obstetrics and gynecology clinics. There were 1465 evaluable participants, 993 women and 472 men. CTQ assay results from female endocervical, self-collected vaginal, male urethral swab specimens, and male and female neat (unpreserved) urine specimens as well as those obtained using the Urine Preservative Transport (UPT) tube for the CTQ assay were compared with patient-infected status (PIS). PIS was determined based on the combined results from Aptima Combo 2 and BD ProbeTec ET CT Amplified DNA Assay. Results: The sensitivity versus PIS for endocervical, vaginal, and both female urine samples was 91.3%, 96.5%, and 93.0%, respectively. The specificity for the same specimen types was 98.3%, 99.2%, and 99.4% (urine neat) and 99.2% (UPT), respectively. The sensitivity versus PIS for male urethral swabs and both male neat and UPT urine were 92.1% and 98%, respectively, with specificities of 98.4%, 99.2%, and 98.1%, respectively. Conclusions: The CTQ assay demonstrated performance characteristics comparable with other commercially available nucleic acid-based tests such as Aptima Combo 2 and BD ProbeTec ET CT-Amplified DNA assay. Vaginal swabs and male urine specimens, the sample types recommended by the Centers for Disease Control for chlamydia screening, both performed at least as well as other sample types evaluated.

Original languageEnglish
Pages (from-to)603-609
Number of pages7
JournalSexually Transmitted Diseases
Volume38
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Chlamydia trachomatis
Urine
Technology
DNA
Chlamydia
Family Planning Services
Centers for Disease Control and Prevention (U.S.)
Sexually Transmitted Diseases
Gynecology
Nucleic Acids
Obstetrics
Multicenter Studies

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Clinical evaluation of the BD probetec™ chlamydia trachomatis Qx amplified DNA assay on the BD viper™ system with XTR™ technology. / Taylor, Stephanie N.; Van Der Pol, Barbara; Lillis, Rebecca; Hook, Edward W.; Lebar, William; Davis, Thomas; Fuller, Deanna; Mena, Leandro; Fine, Paul; Gaydos, Charlotte A.; Martin, David H.

In: Sexually Transmitted Diseases, Vol. 38, No. 7, 07.2011, p. 603-609.

Research output: Contribution to journalArticle

Taylor, SN, Van Der Pol, B, Lillis, R, Hook, EW, Lebar, W, Davis, T, Fuller, D, Mena, L, Fine, P, Gaydos, CA & Martin, DH 2011, 'Clinical evaluation of the BD probetec™ chlamydia trachomatis Qx amplified DNA assay on the BD viper™ system with XTR™ technology', Sexually Transmitted Diseases, vol. 38, no. 7, pp. 603-609. https://doi.org/10.1097/OLQ.0b013e31820a94d2
Taylor, Stephanie N. ; Van Der Pol, Barbara ; Lillis, Rebecca ; Hook, Edward W. ; Lebar, William ; Davis, Thomas ; Fuller, Deanna ; Mena, Leandro ; Fine, Paul ; Gaydos, Charlotte A. ; Martin, David H. / Clinical evaluation of the BD probetec™ chlamydia trachomatis Qx amplified DNA assay on the BD viper™ system with XTR™ technology. In: Sexually Transmitted Diseases. 2011 ; Vol. 38, No. 7. pp. 603-609.
@article{a43237291bde44cbbd21d547270f1bb0,
title = "Clinical evaluation of the BD probetec™ chlamydia trachomatis Qx amplified DNA assay on the BD viper™ system with XTR™ technology",
abstract = "Background: This study evaluated the performance of the BD ProbeTec Chlamydia trachomatis Q (CTQ) Amplified DNA Assay on the BD Viper System with XTR Technology in a multicenter study. Methods: Specimens were collected at 7 geographically diverse clinical sites from 1538 women and men attending sexually transmitted disease, family planning, and obstetrics and gynecology clinics. There were 1465 evaluable participants, 993 women and 472 men. CTQ assay results from female endocervical, self-collected vaginal, male urethral swab specimens, and male and female neat (unpreserved) urine specimens as well as those obtained using the Urine Preservative Transport (UPT) tube for the CTQ assay were compared with patient-infected status (PIS). PIS was determined based on the combined results from Aptima Combo 2 and BD ProbeTec ET CT Amplified DNA Assay. Results: The sensitivity versus PIS for endocervical, vaginal, and both female urine samples was 91.3{\%}, 96.5{\%}, and 93.0{\%}, respectively. The specificity for the same specimen types was 98.3{\%}, 99.2{\%}, and 99.4{\%} (urine neat) and 99.2{\%} (UPT), respectively. The sensitivity versus PIS for male urethral swabs and both male neat and UPT urine were 92.1{\%} and 98{\%}, respectively, with specificities of 98.4{\%}, 99.2{\%}, and 98.1{\%}, respectively. Conclusions: The CTQ assay demonstrated performance characteristics comparable with other commercially available nucleic acid-based tests such as Aptima Combo 2 and BD ProbeTec ET CT-Amplified DNA assay. Vaginal swabs and male urine specimens, the sample types recommended by the Centers for Disease Control for chlamydia screening, both performed at least as well as other sample types evaluated.",
author = "Taylor, {Stephanie N.} and {Van Der Pol}, Barbara and Rebecca Lillis and Hook, {Edward W.} and William Lebar and Thomas Davis and Deanna Fuller and Leandro Mena and Paul Fine and Gaydos, {Charlotte A.} and Martin, {David H.}",
year = "2011",
month = "7",
doi = "10.1097/OLQ.0b013e31820a94d2",
language = "English",
volume = "38",
pages = "603--609",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Clinical evaluation of the BD probetec™ chlamydia trachomatis Qx amplified DNA assay on the BD viper™ system with XTR™ technology

AU - Taylor, Stephanie N.

AU - Van Der Pol, Barbara

AU - Lillis, Rebecca

AU - Hook, Edward W.

AU - Lebar, William

AU - Davis, Thomas

AU - Fuller, Deanna

AU - Mena, Leandro

AU - Fine, Paul

AU - Gaydos, Charlotte A.

AU - Martin, David H.

PY - 2011/7

Y1 - 2011/7

N2 - Background: This study evaluated the performance of the BD ProbeTec Chlamydia trachomatis Q (CTQ) Amplified DNA Assay on the BD Viper System with XTR Technology in a multicenter study. Methods: Specimens were collected at 7 geographically diverse clinical sites from 1538 women and men attending sexually transmitted disease, family planning, and obstetrics and gynecology clinics. There were 1465 evaluable participants, 993 women and 472 men. CTQ assay results from female endocervical, self-collected vaginal, male urethral swab specimens, and male and female neat (unpreserved) urine specimens as well as those obtained using the Urine Preservative Transport (UPT) tube for the CTQ assay were compared with patient-infected status (PIS). PIS was determined based on the combined results from Aptima Combo 2 and BD ProbeTec ET CT Amplified DNA Assay. Results: The sensitivity versus PIS for endocervical, vaginal, and both female urine samples was 91.3%, 96.5%, and 93.0%, respectively. The specificity for the same specimen types was 98.3%, 99.2%, and 99.4% (urine neat) and 99.2% (UPT), respectively. The sensitivity versus PIS for male urethral swabs and both male neat and UPT urine were 92.1% and 98%, respectively, with specificities of 98.4%, 99.2%, and 98.1%, respectively. Conclusions: The CTQ assay demonstrated performance characteristics comparable with other commercially available nucleic acid-based tests such as Aptima Combo 2 and BD ProbeTec ET CT-Amplified DNA assay. Vaginal swabs and male urine specimens, the sample types recommended by the Centers for Disease Control for chlamydia screening, both performed at least as well as other sample types evaluated.

AB - Background: This study evaluated the performance of the BD ProbeTec Chlamydia trachomatis Q (CTQ) Amplified DNA Assay on the BD Viper System with XTR Technology in a multicenter study. Methods: Specimens were collected at 7 geographically diverse clinical sites from 1538 women and men attending sexually transmitted disease, family planning, and obstetrics and gynecology clinics. There were 1465 evaluable participants, 993 women and 472 men. CTQ assay results from female endocervical, self-collected vaginal, male urethral swab specimens, and male and female neat (unpreserved) urine specimens as well as those obtained using the Urine Preservative Transport (UPT) tube for the CTQ assay were compared with patient-infected status (PIS). PIS was determined based on the combined results from Aptima Combo 2 and BD ProbeTec ET CT Amplified DNA Assay. Results: The sensitivity versus PIS for endocervical, vaginal, and both female urine samples was 91.3%, 96.5%, and 93.0%, respectively. The specificity for the same specimen types was 98.3%, 99.2%, and 99.4% (urine neat) and 99.2% (UPT), respectively. The sensitivity versus PIS for male urethral swabs and both male neat and UPT urine were 92.1% and 98%, respectively, with specificities of 98.4%, 99.2%, and 98.1%, respectively. Conclusions: The CTQ assay demonstrated performance characteristics comparable with other commercially available nucleic acid-based tests such as Aptima Combo 2 and BD ProbeTec ET CT-Amplified DNA assay. Vaginal swabs and male urine specimens, the sample types recommended by the Centers for Disease Control for chlamydia screening, both performed at least as well as other sample types evaluated.

UR - http://www.scopus.com/inward/record.url?scp=79959637819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959637819&partnerID=8YFLogxK

U2 - 10.1097/OLQ.0b013e31820a94d2

DO - 10.1097/OLQ.0b013e31820a94d2

M3 - Article

C2 - 21301389

AN - SCOPUS:79959637819

VL - 38

SP - 603

EP - 609

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 7

ER -